Stereotaxis shares surge following trial completion

|By:, SA News Editor

Stereotaxis (STXS) shares storm 37% higher after the company says that it's completed a 120-patient FDA trial for one of its cardiology navigation products - the Vdrive Robotic Navigation System with V-Loop Circular Catheter Manipulator.

The Vdrive with V-Loop system is designed for "remotely controlling the advancement, retraction, rotation, tip deflection, and loop size of a compatible catheter," Stereotaxis says. (PR)